Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple education push prevent 400,000 cancers?

NCT ID NCT07104240

Prevention Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether a program called TweenVax, which provides education and training to clinics, providers, and parents, can increase HPV vaccination rates among adolescents aged 9 to 12. Researchers will compare clinics using TweenVax to those using standard vaccination promotion practices. The goal is to see if more adolescents complete the HPV vaccine series by age 13, potentially preventing many HPV-related cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Educational and promotional intervention (TweenVax) delivered to practices, providers, and parents/adolescents
What this could lead to
If effective, this approach could raise HPV vaccination rates and help prevent hundreds of thousands of HPV-related cancers.
What could go wrong
The trial is early and relies on real-world clinic participation, so results may vary. Success depends on consistent implementation across many practices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,836 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PRACTICE-LEVEL: Must be community based primary care providers (pediatrics or family practice) * PRACTICE-LEVEL: Are willing to be part of the study * PRACTICE-LEVEL: Have sufficient patient population to support 51 adolescents aged 9-12 years over approximately a 9-month period * PRACTICE-LEVEL: Utilize an electronic medical records system and/or report to the state Immunization Information System (IIS) * CHILD/ADOLESCENT: Aged 9-12 years * CHILD/ADOLESCENT: Seeking care from an enrolled practice during the study period * CHILD/ADOLESCENT: Have not received any doses of HPV vaccine by the time of their first visit during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papillomavirus-related carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papillomavirus-related squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papillomavirus-related carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.